Federal Cannabis Rescheduling: Full Policy Landscape

Understanding the current rescheduling effort requires knowing why five previous attempts failed and what is structurally different about this one. The pattern that defined every previous effort was a circular catch-22: the DEA required FDA-approved drug applications demonstrating accepted medical use as the gateway to rescheduling, while Schedule I status itself made the large-scale clinical trials needed for FDA approval essentially impossible to conduct.

1972: The First Petition and the Shafer Commission

NORML filed the first formal rescheduling petition in 1972, the same year Nixon rejected the Shafer Commission’s recommendation against Schedule I placement. The petition entered 16 years of administrative litigation, during which the DEA repeatedly refused to hold the required hearings. A federal court order finally forced the DEA to proceed. DEA Administrative Law Judge Francis Young ruled in 1988 that cannabis was “one of the safest therapeutically active substances known to man” — a finding that would have justified Schedule II placement at minimum. The DEA administrator overrode the ALJ’s recommendation in 1992 and denied the petition, setting a precedent that administrative findings in favor of rescheduling could be ignored by the DEA’s own leadership.

1995 Through 2016: Subsequent Petitions

Three additional petitions were filed in 1995, 2002, and 2011, each denied on the grounds that cannabis lacked FDA-approved drug applications demonstrating accepted medical use. In 2016, the DEA denied the 2011 petition and simultaneously issued a formal policy statement acknowledging that the scheduling system created barriers to the research needed to establish medical use — an official acknowledgment of the circular logic that had defined federal cannabis policy for over four decades. A 2020 federal appellate court ruled the DEA’s refusal to reschedule was not arbitrary and capricious but declined to order action, leaving the policy impasse intact.

What Is Different About the Current Process

The current rescheduling effort is qualitatively different from all previous ones in four ways. First, it is executive-branch-initiated rather than petition-driven — President Biden directed the review by executive order in October 2022, giving it political and institutional momentum that petitions from advocacy organizations never had. Second, the HHS scientific review explicitly concluded that cannabis has a currently accepted medical use — reversing the central finding that had blocked all previous petitions. Third, the accumulated reality of 38 state medical programs serving millions of patients constitutes an empirical record of medical acceptance that did not exist in 1992. Fourth, the DEA published an NPRM rather than simply denying the recommendation, formally committing the agency to the rulemaking process for the first time in history.

The CSA schedules five categories of controlled substances based on accepted medical use and abuse/dependence potential. Understanding where cannabis sits — and where Schedule III sits — requires understanding the full taxonomy.

The SAFE Banking Act (Secure and Fair Enforcement Banking Act) exists because cannabis businesses, despite operating legally under state law, are largely excluded from the federal banking system. Banks and credit unions that knowingly provide services to cannabis businesses face exposure under the Bank Secrecy Act and federal anti-money-laundering statutes, since cannabis remains a Schedule I federal controlled substance. Most major financial institutions have chosen to avoid this exposure entirely, leaving state-licensed cannabis retailers, cultivators, and manufacturers to operate primarily in cash.

The consequences of cash-only operations are severe: physical security risks (cash-heavy businesses are disproportionately robbery targets), inability to make standard payroll payments, no merchant processing for credit or debit cards, inability to obtain business loans or lines of credit, and a complete lack of the financial audit trail that legitimate businesses use to demonstrate compliance. An industry generating approximately $29 billion in annual retail sales operating largely in cash represents a genuine public safety and regulatory compliance failure.

What the SAFE Act Would Provide

The SAFE Banking Act would provide federal safe harbor for financial institutions serving state-licensed cannabis businesses. Specifically, it would prohibit federal regulators from: penalizing or discouraging a bank for providing services to a cannabis-related legitimate business; terminating or limiting deposit insurance for doing so; recommending or incentivizing the termination of a banking relationship; or taking any adverse action against an institution based solely on a customer being a cannabis business. It also provides safe harbor for ancillary service providers (accountants, attorneys, insurance companies) serving cannabis clients.

Legislative History: House Passage, Senate Stall

The SAFE Banking Act has passed the House of Representatives six times with broad bipartisan support — margins ranging from 321–103 to 265–163. Senate passage has been blocked by procedural obstacles and opposition from senators who insist that banking reform should be addressed as part of broader cannabis legalization legislation rather than as a standalone financial services bill. The SAFER Banking Act (an updated version with additional provisions) advanced in the Senate Banking Committee in September 2023 with 14–9 bipartisan support but did not reach the Senate floor before the end of that congressional session.

The banking impasse is one of the clearest examples of the asymmetric political economy of cannabis reform: a policy change with overwhelming bipartisan support and clear business logic has been blocked by a combination of procedural maneuvering and ideological disagreement about the pace of broader legalization.

The Marijuana Opportunity Reinvestment and Expungement Act — the MORE Act — represents a fundamentally different legislative approach from DEA rescheduling. Where rescheduling moves cannabis from Schedule I to Schedule III (a more permissive but still controlled category), the MORE Act would remove cannabis from the CSA entirely — a process called descheduling or descheduled legalization.

What Full Descheduling Would Mean

Full federal descheduling would: end all federal cannabis criminal penalties (possession, cultivation, sale); allow interstate commerce in cannabis products; remove all remaining federal barriers to banking, research, and pharmaceutical development; eliminate Section 280E entirely; permit veterans to access cannabis recommendations through VA physicians; and allow employers to remove cannabis from safety-sensitive drug testing in most contexts (separate regulatory change still needed). It would also create a more explicit conflict with the 1961 UN Single Convention, since the Convention requires maintaining cannabis controls.

The Expungement and Equity Provisions

The MORE Act includes provisions that go beyond rescheduling’s regulatory changes. It would direct federal courts to expunge federal cannabis convictions for activities that would be lawful after passage. It would establish a 5% federal excise tax on cannabis, with revenue directed to social equity programs in communities disproportionately impacted by cannabis enforcement, small business grants for cannabis entrepreneurs from those communities, and youth drug prevention programs. These equity provisions are significant — federal cannabis enforcement has been disproportionately concentrated in Black and Latino communities despite relatively equal rates of use across demographic groups.

MORE Act vs. Rescheduling: Comparison

The state-federal cannabis conflict is one of the most significant unresolved constitutional tensions in American federalism. The Supremacy Clause establishes that federal law is the supreme law of the land when federal and state laws conflict — and cannabis is clearly illegal under federal law while legal in 24 states for recreational use. The Supreme Court resolved the constitutional question in Gonzales v. Raich (2005), holding that the Commerce Clause gives Congress authority to regulate local cannabis cultivation and possession as part of a broader regulatory scheme, even if the activity is entirely intrastate. This means federal prosecution of state-legal cannabis activity is constitutionally permissible.

The practical resolution is the DOJ Cole Memorandum framework. In 2013, Deputy Attorney General James Cole issued a memorandum instructing federal prosecutors to prioritize cannabis enforcement toward eight specific categories (sales to minors, interstate trafficking, cartel involvement, etc.) and to generally defer to state regulatory systems for licensed activity. The Cole Memo was rescinded by Attorney General Jeff Sessions in January 2018, creating a period of uncertainty before the DOJ largely returned to non-enforcement practice without a formal replacement memorandum.

Why the Non-Interference Framework Is Fragile

The critical vulnerability of the state-federal cannabis framework is that it rests entirely on prosecutorial discretion rather than law. Any administration can reverse course without legislative action. Sessions’ 2018 Cole Memo rescission demonstrated this fragility clearly — even though enforcement priorities did not materially change in most states, the announcement created significant uncertainty in the industry and among financial institutions monitoring the legal risk environment. Congressional action codifying the non-enforcement policy, or full descheduling, would replace prosecutorial discretion with statutory protection.

For cannabis businesses, this means the legal risk environment fluctuates with federal administrations in a way that no other regulated industry faces. Building a multi-year business on the assumption that prosecutorial non-interference will continue requires accepting a structural legal risk that most institutional investors and lenders are not comfortable underwriting. This is a key reason why banking and capital access problems persist even in states with mature regulatory frameworks. See our state-by-state cannabis guide for current program status in your jurisdiction.

The United States is a signatory to the 1961 Single Convention on Narcotic Drugs, the foundational international drug control treaty that established the global scheduling system. The Convention classifies cannabis and cannabis resin in the most restrictive tier: Schedule I (high abuse potential, significant liability to abuse) and Schedule IV (particularly dangerous, limited medical/scientific value). Article 4 of the Convention requires parties to limit the production, manufacture, export, import, distribution, trade, use, and possession of scheduled substances exclusively to medical and scientific purposes.

The United States is technically in violation of the Convention with respect to its adult-use cannabis programs in 24 states — a violation that is managed through diplomatic silence rather than acknowledged confrontation. The federal government’s position is that it maintains Schedule I status federally and that state programs operate as state police power matters beyond the federal government’s obligation to preempt. Other signatories have largely accepted this explanation without formally challenging US compliance, partly because several European nations (Netherlands, Luxembourg, Malta, Germany) have adopted policies similarly inconsistent with their treaty obligations.

Article 46: Treaty Withdrawal Mechanism

If the United States were to fully deschedule cannabis and establish a national legal framework, maintaining the Single Convention would require formal treaty renegotiation — a process requiring unanimity among parties that would take years and likely fail given current international drug policy dynamics. Article 46 of the Convention provides a one-year withdrawal mechanism: a nation can withdraw from the Convention on one year’s notice to the UN Secretary-General. Bolivia used this mechanism in 2011 to withdraw in order to protect its traditional coca leaf use, then re-acceded with a specific reservation protecting coca. A similar approach for cannabis would theoretically be available to the United States but would represent a dramatic departure from its historical role as the global drug control framework’s primary architect and enforcer.

The Commission on Narcotic Drugs Vote of 2020

In December 2020, the United Nations Commission on Narcotic Drugs (CND) voted to remove cannabis and cannabis resin from Schedule IV of the 1961 Convention — the most restrictive classification that designated cannabis as having no medical value. By a narrow 27–25 margin, the CND retained cannabis in Schedule I, acknowledging both its medical utility and its abuse potential. The United States voted in favor of the reclassification. While this does not change the Convention’s requirements for national controls, it formally updates the international consensus away from the position that cannabis has no medical value — bringing international policy closer to alignment with the HHS recommendation that drove the current US rescheduling proposal.

For cannabis businesses, the current policy environment creates a unique combination of legal risks and reform opportunities. Understanding the full landscape — rescheduling, banking reform, federal legalization prospects, and treaty constraints — is essential for business planning at any scale.

Immediate Business Impact of Schedule III Reclassification

The removal of Section 280E applicability is the most immediate and quantifiable benefit of rescheduling. Industry estimates suggest that 280E currently costs the legal cannabis industry $2–3 billion in excess federal tax annually. For individual operators, the relief is dramatic: a dispensary paying an effective 60% federal tax rate would normalize to approximately 21% (standard corporate rate), immediately improving net margins by 30+ percentage points. This capital could be redeployed toward workforce compensation, price competitiveness, product development, and the kind of patient education investments that mature the industry.

Capital Markets and Investor Access

Cannabis businesses are currently excluded from most institutional investment due to federal Schedule I status. Many institutional funds, university endowments, pension funds, and publicly traded company investment policies explicitly prohibit cannabis sector exposure while the substance remains federally illegal. Schedule III reclassification, combined with the reduced 280E burden, would likely unlock substantial new capital flows into the sector. Cannabis companies traded on US major exchanges (currently only possible for ancillary businesses, not plant-touching operators) and multi-state operators traded on Canadian exchanges would gain access to a dramatically larger investor base.

The SAFE Act Impact on Operations

SAFE Banking Act passage would enable cannabis businesses to: open standard FDIC-insured commercial bank accounts; accept credit and debit card payments; obtain SBA-backed loans and standard commercial credit; use standard payroll processing; and access insurance products currently unavailable to Schedule I businesses. The operational normalization would reduce physical security costs (fewer cash-in-transit requirements), reduce the premium costs of the limited financial services currently available, and create the paper trail that supports compliance auditing, tax reporting, and potential interstate commerce once legalization advances.

Research and Pharmaceutical Development

For pharmaceutical companies, Schedule III rescheduling opens a commercial pathway that Schedule I has blocked entirely. The FDA-approved cannabis pharmaceutical market currently consists of a single product: GW Pharmaceuticals’ Epidiolex (cannabidiol for severe epilepsy), approved in 2018 under Schedule V. Under Schedule III, private pharmaceutical investment in cannabis-derived medicines across pain management, oncology supportive care, PTSD, and sleep disorders becomes commercially viable for the first time. A mature cannabis pharmaceutical market could produce insurance-covered, physician-prescribed, dosage-calibrated medicines within a decade — an outcome that benefits both patients and the broader legitimization of the cannabis category.